Abstract:Background: Gonadotropin-releasing hormone analogs (GnRHas) are effective in increasing the final height of children with idiopathic central precocious puberty (ICPP). However, in previous years, some transient metabolic complications have been described during this treatment, for which there are no long-term outcome data. Our study aimed to evaluate the efficacy of GnRHas and clarify if body mass index (BMI) at diagnosis of ICPP could influence long-term outcomes. Methods: This was an observational, retrospective study that recruited a cohort of girls with ICPP. Data for anthropometric measures, fasting lipid profile, and glucose metabolism were collected at baseline [when GnRHas treatment started (T1)], at the end of the treatment (T2), and near-final height (nFH) or final height (FH) (T3). Predicted adult height (PAH) was calculated at T1 following Bayley and Pinneau's method. Analysis was carried out using BMI standard deviation score (SDS) categories at T1 (group A, normal weight, vs. group B, overweight/obese). Results: Fifty-seven girls with ICPP who were treated with GnRHas were enrolled in the study (group A vs. group B: 33 vs. 24 patients, aged 7.86 ± 0.81 vs. 7.06 ± 1.61 years, respectively; p < 0.05). In the study population, nFH/FH was in line with the target height (TH) ( p = 0.54), with a mean absolute height gain of 11.82 ± 5.35 cm compared with PAH. Even if the length of therapy was shorter (group A vs. group B: 1.84 ± 2.15 vs. 2.10 ± 0.81 years, respectively; p < 0.05) and the age at menarche was younger (group A vs. group B: 10.56 ± 1.01 vs. 11.44 ± 0.85 years, respectively; p < 0.05) in group B than in group A, the nFH/FH gain was still comparable between the two groups ( p = 0.95). At nFH/FH, BMI SDS was still greater in group B than in group A ( p = 0.012), despite the fact that BMI SDS significantly increased in group A only ( p < 0.05). Glucose metabolism got worst during GnRHa with a complete restoring after it, independently from pre-treatment BMI. The ratio of low-density to high-density lipoprotein cholesterol transiently deteriorated during treatment with GnRHas in group A only ( p = 0.030). Conclusions: Our results confirm the effectiveness of treatment with GnRHas on growth and do not support the concern that being overweight and obese can impair the long-term outcomes of GnRHas therapy. However, the observed transient impairment of metabolic parameters during treatment suggests that clinicians should encourage ICPP girls treated with GnRHas to have a healthy lifestyle, regardless of their pretreatment BMI.

Effects of gonadotropin releasing hormone analogue treatment on final adult height in girls with idiopathic central precocious puberty or advanced puberty

[Long-Acting Gonadotropin-Releasing Hormone Analogue in Treatment of Idiopathic Central Precocious Puberty in Girls].

Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty]

[Impact of Gonadotropin-Releasing Hormone Analogs on Body Mass Index in Girls with Idiopathic Central Precocious Puberty: a Long-Term Follow-Up Study].

Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls

Final adult height and side effects of gonadotropin releasing hormone analogue treatment in 23 girls with idiopathic central precocious puberty

Effects of Gonadotropin-Releasing Hormone Analogs on Height in Girls with Idiopathic Central Precocious Puberty

Application of gonadotropin-releasing hormone analogues in children with central precocious puberty

Effects of Treatment on Female Idiopathic Central Precious Puberty with Gonodotrophine-Releasing Hormone Analogue and Growth Hormone.

Long-term effects of GnRHa on central precocious puberty or early and fast puberty children

The Effects of Gonadotropin-Releasing Hormone Analog and a Combination of Gonadotropin-Releasing Hormone Analog and Recombinant Human Growth Hormone on Adult Height in Girls with Early Puberty

Gonadotropin Releasing Hormone Agonist Treatment to Increase Final Stature in Children with Precocious Puberty: a Meta-Analysis.

Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.

Effect of gonadotropin-releasing hormone agonist treatment in Vietnamese children with central precocious puberty

Effect of Triptorelin 3.75 Mg Subcutaneously Injection Every 6 Weeks on Adult Height in Girls with Idiopathic Central Precocious Puberty

The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis

Relationship of Plasma Ghrelin and Adenohypophyseal Hormone Levels in Female Precocious Puberty

Abstract 29: Effect of gonadotropin releasing hormone analog treatment on final adult height in children with congenital adrenal hyperplasia complicated by central precocious puberty

The impact of BMI on long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHas

Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life